{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:07:35Z","timestamp":1789106855456,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the clinical efficacy, adverse reactions, and physical growth and neurodevelopment effects of oral propranolol in infants with proliferative hemangiomas and to compare these outcomes with those of oral prednisone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 150 infants with proliferative infantile hemangiomas (IHs) treated at our hospital between October 2023 and October 2025. On the basis of outpatient treatment regimens, 77 infants who received oral propranolol were included in the study group, and 73 infants who received oral prednisone were included in the control group. Clinical data, treatment outcomes, adverse reactions, height, weight, head circumference, and neurodevelopment (assessed by using the Gesell Developmental Scale) were collected from medical records. After 3\u20136\u202fmonths of treatment, clinical efficacy was evaluated with the Achauer efficacy grading system, and adverse reactions, physical growth parameters, and neurodevelopmental indicators were compared between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 3\u20136\u202fmonths of treatment, the clinical efficacy in the study group was significantly better than that in the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). The incidence of common adverse reactions, including hypotension, hypoglycemia, constipation, diarrhea, and vomiting, did not significantly differ between the two groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;gt;\u202f0.05). However, the incidence of respiratory tract infections was significantly lower in the study group than in the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). The infants in the study group also had significantly greater height, weight, and head circumference than those in the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). Neurodevelopmental assessment showed that developmental quotients in gross motor, fine motor, adaptive behavior, language, and personal\u2013social domains were all significantly higher in the study group than in the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared with oral prednisone, oral propranolol demonstrates superior therapeutic efficacy in the treatment of proliferative IHs and is associated with fewer respiratory infections and better physical and short-term neurodevelopmental outcomes. These findings suggest that propranolol may offer advantages over prednisone in terms of efficacy, safety, and developmental outcomes, supporting its use as a preferred first-line therapy for proliferative IHs. However, given the limited sample size and short follow-up of this study, large prospective studies are warranted to confirm these observations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1915868","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:31:11Z","timestamp":1789104671000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A comparative analysis of growth and developmental outcomes in infants with proliferative hemangiomas treated with oral propranolol versus prednisone"],"prefix":"10.3389","volume":"14","author":[{"given":"Yanli","family":"Niu","sequence":"first","affiliation":[{"name":"Department of Vascular Anomalies and Interventional Radiology, Ji\u2019nan Children\u2019s Hospital (Children\u2019s Hospital Affiliated to Shandong University)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Vascular Anomalies and Interventional Radiology, Ji\u2019nan Children\u2019s Hospital (Children\u2019s Hospital Affiliated to Shandong University)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Vascular Anomalies and Interventional Radiology, Ji\u2019nan Children\u2019s Hospital (Children\u2019s Hospital Affiliated to Shandong University)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Vascular Anomalies and Interventional Radiology, Ji\u2019nan Children\u2019s Hospital (Children\u2019s Hospital Affiliated to Shandong University)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Vascular Anomalies and Interventional Radiology, Ji\u2019nan Children\u2019s Hospital (Children\u2019s Hospital Affiliated to Shandong University)","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jaad.2021.08.019","article-title":"Infantile hemangioma. Part 1: epidemiology, pathogenesis, clinical presentation and assessment","volume":"85","author":"Rodr\u00edguez Bandera","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.det.2022.06.004","article-title":"Infantile Hemangiomas","volume":"40","author":"Hasbani","year":"2022","journal-title":"Dermatol Clin"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/pde.15363","article-title":"Clinical and epidemiological risk factors for infantile hemangioma: a case-control study","volume":"40","author":"Chehad","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1573396316666200508100038","article-title":"Infantile hemangioma: an updated review","volume":"17","author":"Leung","year":"2021","journal-title":"Curr Pediatr Rev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00105-023-05145-2","article-title":"Infantile hemangioma: Clinical manifestation, treatment, and differential diagnoses","volume":"74","author":"H\u00f6ger","year":"2023","journal-title":"Dermatologie"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"104291","DOI":"10.1016\/j.lpm.2025.104291","article-title":"Diagnosis and management of infantile hemangiomas: tremendous advances over the last 15 years","volume":"54","author":"Canu","year":"2025","journal-title":"Presse Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.4103\/jfmpc.jfmpc_641_22","article-title":"Epithelioid hemangioma (ALHE) on the tongue of an infant treated with oral corticosteroids: a case report and review of the literature","volume":"12","author":"Ansari","year":"2023","journal-title":"J Family Med Prim Care"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e5506","DOI":"10.1097\/GOX.0000000000005506","article-title":"Infantile hemangioma of the breast: long-term assessment of outcomes","volume":"12","author":"Labow","year":"2024","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.3928\/19382359-20230307-02","article-title":"Infantile hemangiomas: a review of current treatment options","volume":"52","author":"Dahan","year":"2023","journal-title":"Pediatr Ann"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/PRS.0000000000007699","article-title":"Propranolol therapy in infantile hemangioma: it is not just about the Beta","volume":"147","author":"Lee","year":"2021","journal-title":"Plast Reconstr Surg"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/pde.15753","article-title":"Safety of prior propranolol therapy for infantile hemangioma","volume":"41","author":"Hasan","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"6669383","DOI":"10.1155\/2021\/6669383","article-title":"Propranolol for treatment of infantile hemangioma: efficacy and effect on pediatric growth and development","volume":"2021","author":"Giese","year":"2021","journal-title":"Int J Pediatr"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e33998","DOI":"10.1097\/MD.0000000000033998","article-title":"The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment","volume":"102","author":"Lin","year":"2023","journal-title":"Medicine"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s12098-023-04586-w","article-title":"Oral propranolol therapy for infantile hemangioma: long-term follow-up","volume":"90","author":"Yenamandra","year":"2023","journal-title":"Indian J Pediatr"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00431-020-03872-5","article-title":"Recurrence rate of infantile hemangioma after oral propranolol therapy","volume":"180","author":"Frongia","year":"2021","journal-title":"Eur J Pediatr"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e75806","DOI":"10.7759\/cureus.75806","article-title":"Optimizing propranolol therapy for infantile hemangiomas: the role of the multidisciplinary team","volume":"16","author":"Yasuda-Koiwa","year":"2024","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/gpbjnl\/qzag023","article-title":"Single-cell RNA sequencing discovered subtypes associated with angiogenesis and propranolol treatment in infantile hemangioma","author":"Chen","year":"2026","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1439449","DOI":"10.3389\/fmed.2024.1439449","article-title":"Oral propranolol for the treatment of hemangiomas in high-risk infants: safety and cost analysis of outpatient-initiated therapy","volume":"11","author":"Su","year":"2024","journal-title":"Front Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/pde.15652","article-title":"The burden of treatment of propranolol for infantile hemangiomas: a mixed methods study","volume":"41","author":"O'Connor","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"24253","DOI":"10.1038\/s41598-025-07577-3","article-title":"Cardiovascular safety of propranolol oral solution in infantile hemangiomas: a disproportionality analysis based on the FAERS database","volume":"15","author":"Nie","year":"2025","journal-title":"Sci Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"112576","DOI":"10.1016\/j.ijporl.2025.112576","article-title":"Assessing the effectiveness of propranolol in treating pediatric airway hemangiomas: a systematic review and meta-analysis","volume":"198","author":"Herberger","year":"2025","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1159\/000542001","article-title":"Rebound growth of infantile hemangiomas after propranolol versus atenolol treatment: a retrospective study","volume":"240","author":"Baruch","year":"2024","journal-title":"Dermatology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.jpedsurg.2013.08.020","article-title":"Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study","volume":"48","author":"Malik","year":"2013","journal-title":"J Pediatr Surg"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/ddg.13365_g","article-title":"Infantile hemangioma: pathogenesis and mechanisms of action of propranolol","volume":"15","author":"Rotter","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2671601","DOI":"10.1080\/09546634.2026.2671601","article-title":"Oral propranolol treatment safety in infantile hemangiomas","volume":"37","author":"Alsuwaidan","year":"2026","journal-title":"J Dermatolog Treat"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1007\/s43440-025-00762-1","article-title":"Early plasma changes of HIF-1 alpha, matrix metalloproteinases-2 and -\u202f9, and tissue inhibitor of matrix metalloproteinase-1 in patients with infantile hemangiomas treated with propranolol","volume":"77","author":"Kowalska","year":"2025","journal-title":"Pharmacol Rep"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1119427","DOI":"10.3389\/fendo.2023.1119427","article-title":"Glucocorticoid induced bone disorders in children: research progress in treatment mechanisms","volume":"14","author":"Hua","year":"2023","journal-title":"Front Endocrinol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/children11121557","article-title":"Neurodevelopmental effects of propranolol treatment during infancy in infantile hemangioma patients","volume":"11","author":"Baykan","year":"2024","journal-title":"Children"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00431-022-04674-7","article-title":"Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma","volume":"182","author":"Hermans","year":"2023","journal-title":"Eur J Pediatr"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1915868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:31:11Z","timestamp":1789104671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1915868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":30,"alternative-id":["10.3389\/fpubh.2026.1915868"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1915868","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"1915868"}}